{"transactions":[{"id":2904807,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":143703,"kind":"organization","name":"Mayne Pharma Ventures Pty Ltd","position":1,"cik":"0001611535","reported_name":"Mayne Pharma Ventures Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143704,"kind":"organization","name":"Mayne Pharma International Pty Ltd","position":2,"cik":"0001611534","reported_name":"Mayne Pharma International Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143705,"kind":"organization","name":"Mayne Pharma Group Ltd","position":3,"cik":"0001560183","reported_name":"Mayne Pharma Group Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-01-19T18:50:50.000Z","date":"2021-01-15","kind":"other","acquired":true,"shares":2240488,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 15, 2021, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") received a dividend of 2,240,488 shares of Common Stock paid by the Issuer on shares of Series B Convertible Preferred Stock held by Mayne Ventures, pursuant to the terms of such Series B Convertible Preferred Stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd (\"Mayne International\") and Mayne Pharma Group Limited (\"Mayne Group\"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures may be deemed to be a director by deputization by virtue of its representation on the Board of Directors of the Issuer."}],"balance_after":204083227,"source":{"system":"sec-edgar","filing":"0001104659-21-005226","document":"tm213575d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000110465921005226/tm213575d1_4.xml","form_type":"4"}},{"id":3079741,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":143703,"kind":"organization","name":"Mayne Pharma Ventures Pty Ltd","position":1,"cik":"0001611535","reported_name":"Mayne Pharma Ventures Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143704,"kind":"organization","name":"Mayne Pharma International Pty Ltd","position":2,"cik":"0001611534","reported_name":"Mayne Pharma International Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143705,"kind":"organization","name":"Mayne Pharma Group Ltd","position":3,"cik":"0001560183","reported_name":"Mayne Pharma Group Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-21T01:56:46.000Z","date":"2020-07-15","kind":"other","acquired":true,"shares":3189688,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 15, 2020, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") received a dividend of 3,189,688 shares of Common Stock paid by the Issuer on shares of Series B Convertible Preferred Stock held by Mayne Ventures, pursuant to the terms of such Series B Convertible Preferred Stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd (\"Mayne International\") and Mayne Pharma Group Limited (\"Mayne Group\"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures may be deemed to be a director by deputization by virtue of its representation on the Board of Directors of the Issuer."}],"balance_after":201842739,"source":{"system":"sec-edgar","filing":"0001104659-20-084975","document":"tm2025270d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000110465920084975/tm2025270d1_4.xml","form_type":"4"}},{"id":3688263,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":143703,"kind":"organization","name":"Mayne Pharma Ventures Pty Ltd","position":1,"cik":"0001611535","reported_name":"Mayne Pharma Ventures Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143704,"kind":"organization","name":"Mayne Pharma International Pty Ltd","position":2,"cik":"0001611534","reported_name":"Mayne Pharma International Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143705,"kind":"organization","name":"Mayne Pharma Group Ltd","position":3,"cik":"0001560183","reported_name":"Mayne Pharma Group Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-01-25T00:49:58.000Z","date":"2019-01-15","kind":"other","acquired":true,"shares":362121,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 15, 2019, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") received a dividend of 362,121 shares of Common Stock paid by the Issuer on shares of Series B Convertible Preferred Stock held by Mayne Ventures, pursuant to the terms of such Series B Convertible Preferred Stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd (\"Mayne International\") and Mayne Pharma Group Limited (\"Mayne Group\"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer."}],"balance_after":198653051,"source":{"system":"sec-edgar","filing":"0001144204-19-002698","document":"tv511589_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000114420419002698/tv511589_4.xml","form_type":"4"}},{"id":3725317,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":143703,"kind":"organization","name":"Mayne Pharma Ventures Pty Ltd","position":1,"cik":"0001611535","reported_name":"Mayne Pharma Ventures Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143704,"kind":"organization","name":"Mayne Pharma International Pty Ltd","position":2,"cik":"0001611534","reported_name":"Mayne Pharma International Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143705,"kind":"organization","name":"Mayne Pharma Group Ltd","position":3,"cik":"0001560183","reported_name":"Mayne Pharma Group Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-12-19T11:09:33.000Z","date":"2018-07-15","kind":"other","acquired":true,"shares":184798,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 15, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") received a dividend of 184,798 shares of Common Stock paid by the Issuer on shares of Series B Convertible Preferred Stock held by Mayne Ventures, pursuant to the terms of such Series B Convertible Preferred Stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd (\"Mayne International\") and Mayne Pharma Group Limited (\"Mayne Group\"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer."}],"balance_after":198290930,"source":{"system":"sec-edgar","filing":"0001144204-18-065264","document":"tv509462_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000114420418065264/tv509462_4.xml","form_type":"4"}},{"id":3871929,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":143703,"kind":"organization","name":"Mayne Pharma Ventures Pty Ltd","position":1,"cik":"0001611535","reported_name":"Mayne Pharma Ventures Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143704,"kind":"organization","name":"Mayne Pharma International Pty Ltd","position":2,"cik":"0001611534","reported_name":"Mayne Pharma International Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143705,"kind":"organization","name":"Mayne Pharma Group Ltd","position":3,"cik":"0001560183","reported_name":"Mayne Pharma Group Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrants to Purchase Common Stock","published_at":"2018-07-06T21:11:47.000Z","date":"2018-07-05","kind":"purchase","acquired":true,"shares":1739131,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series B warrants have an initial exercise price of US$0.275 and may be exercised by Mayne Ventures at any time prior to their expiration on July 5, 2023."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 5, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired (i) 2,318,841 shares of Series B Convertible Preferred Stock, (ii) Series A warrants to purchase 1,739,131 shares of Common Stock in the aggregate and (iii) Series B warrants to purchase 1,739,131 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$1,600,000 at the second closing pursuant to the terms of the securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"shares","element":"transactionShares","label":"F1","text":"On July 5, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired (i) 2,318,841 shares of Series B Convertible Preferred Stock, (ii) Series A warrants to purchase 1,739,131 shares of Common Stock in the aggregate and (iii) Series B warrants to purchase 1,739,131 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$1,600,000 at the second closing pursuant to the terms of the securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 5, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired (i) 2,318,841 shares of Series B Convertible Preferred Stock, (ii) Series A warrants to purchase 1,739,131 shares of Common Stock in the aggregate and (iii) Series B warrants to purchase 1,739,131 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$1,600,000 at the second closing pursuant to the terms of the securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series B warrants have an initial exercise price of US$0.275 and may be exercised by Mayne Ventures at any time prior to their expiration on July 5, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On July 5, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired (i) 2,318,841 shares of Series B Convertible Preferred Stock, (ii) Series A warrants to purchase 1,739,131 shares of Common Stock in the aggregate and (iii) Series B warrants to purchase 1,739,131 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$1,600,000 at the second closing pursuant to the terms of the securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd (\"Mayne International\") and Mayne Pharma Group Limited (\"Mayne Group\"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer."}],"balance_after":1739131,"derivative":{"exercise_price":0.275,"exercise_date":"2018-07-05","expiration_date":"2023-07-05","underlying":"Common Stock","underlying_shares":1739131},"source":{"system":"sec-edgar","filing":"0001144204-18-037560","document":"tv498045_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000114420418037560/tv498045_4.xml","form_type":"4"}},{"id":3871928,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":143703,"kind":"organization","name":"Mayne Pharma Ventures Pty Ltd","position":1,"cik":"0001611535","reported_name":"Mayne Pharma Ventures Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143704,"kind":"organization","name":"Mayne Pharma International Pty Ltd","position":2,"cik":"0001611534","reported_name":"Mayne Pharma International Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143705,"kind":"organization","name":"Mayne Pharma Group Ltd","position":3,"cik":"0001560183","reported_name":"Mayne Pharma Group Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrants to Purchase Common Stock","published_at":"2018-07-06T21:11:47.000Z","date":"2018-07-05","kind":"purchase","acquired":true,"shares":1739131,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A warrants have an initial exercise price of US$0.23 and may be exercised by Mayne Ventures at any time prior to their expiration on July 5, 2020."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 5, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired (i) 2,318,841 shares of Series B Convertible Preferred Stock, (ii) Series A warrants to purchase 1,739,131 shares of Common Stock in the aggregate and (iii) Series B warrants to purchase 1,739,131 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$1,600,000 at the second closing pursuant to the terms of the securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"shares","element":"transactionShares","label":"F1","text":"On July 5, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired (i) 2,318,841 shares of Series B Convertible Preferred Stock, (ii) Series A warrants to purchase 1,739,131 shares of Common Stock in the aggregate and (iii) Series B warrants to purchase 1,739,131 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$1,600,000 at the second closing pursuant to the terms of the securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 5, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired (i) 2,318,841 shares of Series B Convertible Preferred Stock, (ii) Series A warrants to purchase 1,739,131 shares of Common Stock in the aggregate and (iii) Series B warrants to purchase 1,739,131 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$1,600,000 at the second closing pursuant to the terms of the securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series A warrants have an initial exercise price of US$0.23 and may be exercised by Mayne Ventures at any time prior to their expiration on July 5, 2020."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On July 5, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired (i) 2,318,841 shares of Series B Convertible Preferred Stock, (ii) Series A warrants to purchase 1,739,131 shares of Common Stock in the aggregate and (iii) Series B warrants to purchase 1,739,131 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$1,600,000 at the second closing pursuant to the terms of the securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd (\"Mayne International\") and Mayne Pharma Group Limited (\"Mayne Group\"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer."}],"balance_after":1739131,"derivative":{"exercise_price":0.23,"exercise_date":"2018-07-05","expiration_date":"2020-07-05","underlying":"Common Stock","underlying_shares":1739131},"source":{"system":"sec-edgar","filing":"0001144204-18-037560","document":"tv498045_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000114420418037560/tv498045_4.xml","form_type":"4"}},{"id":3871927,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":143703,"kind":"organization","name":"Mayne Pharma Ventures Pty Ltd","position":1,"cik":"0001611535","reported_name":"Mayne Pharma Ventures Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143704,"kind":"organization","name":"Mayne Pharma International Pty Ltd","position":2,"cik":"0001611534","reported_name":"Mayne Pharma International Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143705,"kind":"organization","name":"Mayne Pharma Group Ltd","position":3,"cik":"0001560183","reported_name":"Mayne Pharma Group Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2018-07-06T21:11:47.000Z","date":"2018-07-05","kind":"purchase","acquired":true,"shares":2318841,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 5, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired (i) 2,318,841 shares of Series B Convertible Preferred Stock, (ii) Series A warrants to purchase 1,739,131 shares of Common Stock in the aggregate and (iii) Series B warrants to purchase 1,739,131 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$1,600,000 at the second closing pursuant to the terms of the securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 5, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired (i) 2,318,841 shares of Series B Convertible Preferred Stock, (ii) Series A warrants to purchase 1,739,131 shares of Common Stock in the aggregate and (iii) Series B warrants to purchase 1,739,131 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$1,600,000 at the second closing pursuant to the terms of the securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"shares","element":"transactionShares","label":"F1","text":"On July 5, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired (i) 2,318,841 shares of Series B Convertible Preferred Stock, (ii) Series A warrants to purchase 1,739,131 shares of Common Stock in the aggregate and (iii) Series B warrants to purchase 1,739,131 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$1,600,000 at the second closing pursuant to the terms of the securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 5, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired (i) 2,318,841 shares of Series B Convertible Preferred Stock, (ii) Series A warrants to purchase 1,739,131 shares of Common Stock in the aggregate and (iii) Series B warrants to purchase 1,739,131 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$1,600,000 at the second closing pursuant to the terms of the securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 5, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired (i) 2,318,841 shares of Series B Convertible Preferred Stock, (ii) Series A warrants to purchase 1,739,131 shares of Common Stock in the aggregate and (iii) Series B warrants to purchase 1,739,131 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$1,600,000 at the second closing pursuant to the terms of the securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On July 5, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired (i) 2,318,841 shares of Series B Convertible Preferred Stock, (ii) Series A warrants to purchase 1,739,131 shares of Common Stock in the aggregate and (iii) Series B warrants to purchase 1,739,131 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$1,600,000 at the second closing pursuant to the terms of the securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd (\"Mayne International\") and Mayne Pharma Group Limited (\"Mayne Group\"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer."}],"balance_after":5797102,"derivative":{"exercise_date":"2018-07-05","underlying":"Common Stock","underlying_shares":6956523},"source":{"system":"sec-edgar","filing":"0001144204-18-037560","document":"tv498045_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000114420418037560/tv498045_4.xml","form_type":"4"}},{"id":4066472,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":143703,"kind":"organization","name":"Mayne Pharma Ventures Pty Ltd","position":1,"cik":"0001611535","reported_name":"Mayne Pharma Ventures Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143704,"kind":"organization","name":"Mayne Pharma International Pty Ltd","position":2,"cik":"0001611534","reported_name":"Mayne Pharma International Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143705,"kind":"organization","name":"Mayne Pharma Group Ltd","position":3,"cik":"0001560183","reported_name":"Mayne Pharma Group Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-02-13T00:47:01.000Z","date":"2017-12-19","kind":"purchase","acquired":true,"shares":600000,"price":162660,"value":97596000000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 19, 2017, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 600,000 shares of Common Stock from Stefan Cross."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd (\"Mayne International\") and Mayne Pharma Group Limited (\"Mayne Group\"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer."}],"balance_after":198106132,"source":{"system":"sec-edgar","filing":"0001144204-18-007440","document":"tv485756_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000114420418007440/tv485756_4.xml","form_type":"4"}},{"id":4101477,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":143703,"kind":"organization","name":"Mayne Pharma Ventures Pty Ltd","position":1,"cik":"0001611535","reported_name":"Mayne Pharma Ventures Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143704,"kind":"organization","name":"Mayne Pharma International Pty Ltd","position":2,"cik":"0001611534","reported_name":"Mayne Pharma International Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143705,"kind":"organization","name":"Mayne Pharma Group Ltd","position":3,"cik":"0001560183","reported_name":"Mayne Pharma Group Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrants to Purchase Common Stock","published_at":"2018-01-11T14:21:42.000Z","date":"2018-01-10","kind":"purchase","acquired":true,"shares":2608696,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series B warrants have an initial exercise price of US$0.275 and may be exercised by Mayne Ventures at any time prior to their expiration on January 10, 2023."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 10, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 3,478,261 shares of Series B Convertible Preferred Stock, Series A warrants to purchase 2,608,696 shares of Common Stock in the aggregate and Series B warrants to purchase 2,608,696 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$2,400,000 pursuant to the terms of a securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"shares","element":"transactionShares","label":"F1","text":"On January 10, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 3,478,261 shares of Series B Convertible Preferred Stock, Series A warrants to purchase 2,608,696 shares of Common Stock in the aggregate and Series B warrants to purchase 2,608,696 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$2,400,000 pursuant to the terms of a securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 10, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 3,478,261 shares of Series B Convertible Preferred Stock, Series A warrants to purchase 2,608,696 shares of Common Stock in the aggregate and Series B warrants to purchase 2,608,696 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$2,400,000 pursuant to the terms of a securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series B warrants have an initial exercise price of US$0.275 and may be exercised by Mayne Ventures at any time prior to their expiration on January 10, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On January 10, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 3,478,261 shares of Series B Convertible Preferred Stock, Series A warrants to purchase 2,608,696 shares of Common Stock in the aggregate and Series B warrants to purchase 2,608,696 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$2,400,000 pursuant to the terms of a securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd (\"Mayne International\") and Mayne Pharma Group Limited (\"Mayne Group\"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer."}],"balance_after":2608696,"derivative":{"exercise_price":0.275,"exercise_date":"2018-01-10","expiration_date":"2023-01-10","underlying":"Common Stock","underlying_shares":2608696},"source":{"system":"sec-edgar","filing":"0001144204-18-001823","document":"tv483130_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000114420418001823/tv483130_4.xml","form_type":"4"}},{"id":4101476,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":143703,"kind":"organization","name":"Mayne Pharma Ventures Pty Ltd","position":1,"cik":"0001611535","reported_name":"Mayne Pharma Ventures Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143704,"kind":"organization","name":"Mayne Pharma International Pty Ltd","position":2,"cik":"0001611534","reported_name":"Mayne Pharma International Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143705,"kind":"organization","name":"Mayne Pharma Group Ltd","position":3,"cik":"0001560183","reported_name":"Mayne Pharma Group Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrants to Purchase Common Stock","published_at":"2018-01-11T14:21:42.000Z","date":"2018-01-10","kind":"purchase","acquired":true,"shares":2608696,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A warrants have an initial exercise price of US$0.23 and may be exercised by Mayne Ventures at any time prior to their expiration on January 10, 2020."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 10, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 3,478,261 shares of Series B Convertible Preferred Stock, Series A warrants to purchase 2,608,696 shares of Common Stock in the aggregate and Series B warrants to purchase 2,608,696 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$2,400,000 pursuant to the terms of a securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"shares","element":"transactionShares","label":"F1","text":"On January 10, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 3,478,261 shares of Series B Convertible Preferred Stock, Series A warrants to purchase 2,608,696 shares of Common Stock in the aggregate and Series B warrants to purchase 2,608,696 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$2,400,000 pursuant to the terms of a securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 10, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 3,478,261 shares of Series B Convertible Preferred Stock, Series A warrants to purchase 2,608,696 shares of Common Stock in the aggregate and Series B warrants to purchase 2,608,696 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$2,400,000 pursuant to the terms of a securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series A warrants have an initial exercise price of US$0.23 and may be exercised by Mayne Ventures at any time prior to their expiration on January 10, 2020."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On January 10, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 3,478,261 shares of Series B Convertible Preferred Stock, Series A warrants to purchase 2,608,696 shares of Common Stock in the aggregate and Series B warrants to purchase 2,608,696 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$2,400,000 pursuant to the terms of a securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd (\"Mayne International\") and Mayne Pharma Group Limited (\"Mayne Group\"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer."}],"balance_after":2608696,"derivative":{"exercise_price":0.23,"exercise_date":"2018-01-10","expiration_date":"2020-01-10","underlying":"Common Stock","underlying_shares":2608696},"source":{"system":"sec-edgar","filing":"0001144204-18-001823","document":"tv483130_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000114420418001823/tv483130_4.xml","form_type":"4"}},{"id":4101475,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":143703,"kind":"organization","name":"Mayne Pharma Ventures Pty Ltd","position":1,"cik":"0001611535","reported_name":"Mayne Pharma Ventures Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143704,"kind":"organization","name":"Mayne Pharma International Pty Ltd","position":2,"cik":"0001611534","reported_name":"Mayne Pharma International Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143705,"kind":"organization","name":"Mayne Pharma Group Ltd","position":3,"cik":"0001560183","reported_name":"Mayne Pharma Group Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2018-01-11T14:21:42.000Z","date":"2018-01-10","kind":"purchase","acquired":true,"shares":3478261,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On January 10, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 3,478,261 shares of Series B Convertible Preferred Stock, Series A warrants to purchase 2,608,696 shares of Common Stock in the aggregate and Series B warrants to purchase 2,608,696 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$2,400,000 pursuant to the terms of a securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 10, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 3,478,261 shares of Series B Convertible Preferred Stock, Series A warrants to purchase 2,608,696 shares of Common Stock in the aggregate and Series B warrants to purchase 2,608,696 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$2,400,000 pursuant to the terms of a securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"shares","element":"transactionShares","label":"F1","text":"On January 10, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 3,478,261 shares of Series B Convertible Preferred Stock, Series A warrants to purchase 2,608,696 shares of Common Stock in the aggregate and Series B warrants to purchase 2,608,696 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$2,400,000 pursuant to the terms of a securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 10, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 3,478,261 shares of Series B Convertible Preferred Stock, Series A warrants to purchase 2,608,696 shares of Common Stock in the aggregate and Series B warrants to purchase 2,608,696 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$2,400,000 pursuant to the terms of a securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On January 10, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 3,478,261 shares of Series B Convertible Preferred Stock, Series A warrants to purchase 2,608,696 shares of Common Stock in the aggregate and Series B warrants to purchase 2,608,696 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$2,400,000 pursuant to the terms of a securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On January 10, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 3,478,261 shares of Series B Convertible Preferred Stock, Series A warrants to purchase 2,608,696 shares of Common Stock in the aggregate and Series B warrants to purchase 2,608,696 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$2,400,000 pursuant to the terms of a securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd (\"Mayne International\") and Mayne Pharma Group Limited (\"Mayne Group\"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer."}],"balance_after":3478261,"derivative":{"exercise_date":"2018-01-10","underlying":"Common Stock","underlying_shares":10434783},"source":{"system":"sec-edgar","filing":"0001144204-18-001823","document":"tv483130_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000114420418001823/tv483130_4.xml","form_type":"4"}},{"id":4555516,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":143703,"kind":"organization","name":"Mayne Pharma Ventures Pty Ltd","position":1,"cik":"0001611535","reported_name":"Mayne Pharma Ventures Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143704,"kind":"organization","name":"Mayne Pharma International Pty Ltd","position":2,"cik":"0001611534","reported_name":"Mayne Pharma International Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143705,"kind":"organization","name":"Mayne Pharma Group Ltd","position":3,"cik":"0001560183","reported_name":"Mayne Pharma Group Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to Purchase Common Stock","published_at":"2016-11-16T02:06:30.000Z","date":"2016-11-15","kind":"other","acquired":false,"shares":4860000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"On November 15, 2016, Mayne Ventures acquired 4,860,000 shares of Common Stock for an aggregate purchase price of $583,200 through the partial exercise of a warrant (at a per share exercise price of $0.12) that was issued by the Issuer to Mayne Ventures on May 25, 2016 (the \"2016 Warrant\"). 23,504,236 shares of Common Stock remain issuable upon exercise of the 2016 Warrant. The 2016 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time on or prior to May 25, 2021."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On November 15, 2016, Mayne Ventures acquired 4,860,000 shares of Common Stock for an aggregate purchase price of $583,200 through the partial exercise of a warrant (at a per share exercise price of $0.12) that was issued by the Issuer to Mayne Ventures on May 25, 2016 (the \"2016 Warrant\"). 23,504,236 shares of Common Stock remain issuable upon exercise of the 2016 Warrant. The 2016 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time on or prior to May 25, 2021."},{"field":"shares","element":"transactionShares","label":"F3","text":"On November 15, 2016, Mayne Ventures acquired 4,860,000 shares of Common Stock for an aggregate purchase price of $583,200 through the partial exercise of a warrant (at a per share exercise price of $0.12) that was issued by the Issuer to Mayne Ventures on May 25, 2016 (the \"2016 Warrant\"). 23,504,236 shares of Common Stock remain issuable upon exercise of the 2016 Warrant. The 2016 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time on or prior to May 25, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On November 15, 2016, Mayne Ventures acquired 4,860,000 shares of Common Stock for an aggregate purchase price of $583,200 through the partial exercise of a warrant (at a per share exercise price of $0.12) that was issued by the Issuer to Mayne Ventures on May 25, 2016 (the \"2016 Warrant\"). 23,504,236 shares of Common Stock remain issuable upon exercise of the 2016 Warrant. The 2016 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time on or prior to May 25, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On November 15, 2016, Mayne Ventures acquired 4,860,000 shares of Common Stock for an aggregate purchase price of $583,200 through the partial exercise of a warrant (at a per share exercise price of $0.12) that was issued by the Issuer to Mayne Ventures on May 25, 2016 (the \"2016 Warrant\"). 23,504,236 shares of Common Stock remain issuable upon exercise of the 2016 Warrant. The 2016 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time on or prior to May 25, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On November 15, 2016, Mayne Ventures acquired 4,860,000 shares of Common Stock for an aggregate purchase price of $583,200 through the partial exercise of a warrant (at a per share exercise price of $0.12) that was issued by the Issuer to Mayne Ventures on May 25, 2016 (the \"2016 Warrant\"). 23,504,236 shares of Common Stock remain issuable upon exercise of the 2016 Warrant. The 2016 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time on or prior to May 25, 2021."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"On November 15, 2016, Mayne Ventures acquired 4,860,000 shares of Common Stock for an aggregate purchase price of $583,200 through the partial exercise of a warrant (at a per share exercise price of $0.12) that was issued by the Issuer to Mayne Ventures on May 25, 2016 (the \"2016 Warrant\"). 23,504,236 shares of Common Stock remain issuable upon exercise of the 2016 Warrant. The 2016 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time on or prior to May 25, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"On November 15, 2016, Mayne Ventures acquired 4,860,000 shares of Common Stock for an aggregate purchase price of $583,200 through the partial exercise of a warrant (at a per share exercise price of $0.12) that was issued by the Issuer to Mayne Ventures on May 25, 2016 (the \"2016 Warrant\"). 23,504,236 shares of Common Stock remain issuable upon exercise of the 2016 Warrant. The 2016 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time on or prior to May 25, 2021."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd (\"Mayne International\") and Mayne Pharma Group Limited (\"Mayne Group\"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer."}],"balance_after":23504236,"derivative":{"exercise_price":0.12,"underlying":"Common Stock","underlying_shares":4860000},"source":{"system":"sec-edgar","filing":"0001144204-16-134828","document":"v453196_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000114420416134828/v453196_4.xml","form_type":"4"}},{"id":4555515,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":143703,"kind":"organization","name":"Mayne Pharma Ventures Pty Ltd","position":1,"cik":"0001611535","reported_name":"Mayne Pharma Ventures Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143704,"kind":"organization","name":"Mayne Pharma International Pty Ltd","position":2,"cik":"0001611534","reported_name":"Mayne Pharma International Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143705,"kind":"organization","name":"Mayne Pharma Group Ltd","position":3,"cik":"0001560183","reported_name":"Mayne Pharma Group Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to Purchase Common Stock","published_at":"2016-11-16T02:06:30.000Z","date":"2016-11-15","kind":"other","acquired":false,"shares":333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"On November 15, 2016, Mayne Ventures acquired 333 shares of Common Stock for an aggregate purchase price of $24.98 through the exercise of a warrant (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015 (the \"2015 Warrant\"). No shares of Common Stock remain issuable upon exercise of the 2015 Warrant."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On November 15, 2016, Mayne Ventures acquired 333 shares of Common Stock for an aggregate purchase price of $24.98 through the exercise of a warrant (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015 (the \"2015 Warrant\"). No shares of Common Stock remain issuable upon exercise of the 2015 Warrant."},{"field":"shares","element":"transactionShares","label":"F2","text":"On November 15, 2016, Mayne Ventures acquired 333 shares of Common Stock for an aggregate purchase price of $24.98 through the exercise of a warrant (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015 (the \"2015 Warrant\"). No shares of Common Stock remain issuable upon exercise of the 2015 Warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On November 15, 2016, Mayne Ventures acquired 333 shares of Common Stock for an aggregate purchase price of $24.98 through the exercise of a warrant (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015 (the \"2015 Warrant\"). No shares of Common Stock remain issuable upon exercise of the 2015 Warrant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On November 15, 2016, Mayne Ventures acquired 333 shares of Common Stock for an aggregate purchase price of $24.98 through the exercise of a warrant (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015 (the \"2015 Warrant\"). No shares of Common Stock remain issuable upon exercise of the 2015 Warrant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On November 15, 2016, Mayne Ventures acquired 333 shares of Common Stock for an aggregate purchase price of $24.98 through the exercise of a warrant (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015 (the \"2015 Warrant\"). No shares of Common Stock remain issuable upon exercise of the 2015 Warrant."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On November 15, 2016, Mayne Ventures acquired 333 shares of Common Stock for an aggregate purchase price of $24.98 through the exercise of a warrant (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015 (the \"2015 Warrant\"). No shares of Common Stock remain issuable upon exercise of the 2015 Warrant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On November 15, 2016, Mayne Ventures acquired 333 shares of Common Stock for an aggregate purchase price of $24.98 through the exercise of a warrant (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015 (the \"2015 Warrant\"). No shares of Common Stock remain issuable upon exercise of the 2015 Warrant."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd (\"Mayne International\") and Mayne Pharma Group Limited (\"Mayne Group\"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":0.075,"underlying":"Common Stock","underlying_shares":333},"source":{"system":"sec-edgar","filing":"0001144204-16-134828","document":"v453196_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000114420416134828/v453196_4.xml","form_type":"4"}},{"id":4555514,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":143703,"kind":"organization","name":"Mayne Pharma Ventures Pty Ltd","position":1,"cik":"0001611535","reported_name":"Mayne Pharma Ventures Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143704,"kind":"organization","name":"Mayne Pharma International Pty Ltd","position":2,"cik":"0001611534","reported_name":"Mayne Pharma International Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143705,"kind":"organization","name":"Mayne Pharma Group Ltd","position":3,"cik":"0001560183","reported_name":"Mayne Pharma Group Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to Purchase Common Stock","published_at":"2016-11-16T02:06:30.000Z","date":"2016-11-15","kind":"other","acquired":false,"shares":4750569,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On November 15, 2016, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 4,750,569 shares of Common Stock for an aggregate purchase price of $417,099.96 through the exercise of a warrant (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the \"2014 Warrant\"). Following such exercise, no shares of Common Stock remain issuable upon exercise of the 2014 Warrant."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On November 15, 2016, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 4,750,569 shares of Common Stock for an aggregate purchase price of $417,099.96 through the exercise of a warrant (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the \"2014 Warrant\"). Following such exercise, no shares of Common Stock remain issuable upon exercise of the 2014 Warrant."},{"field":"shares","element":"transactionShares","label":"F1","text":"On November 15, 2016, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 4,750,569 shares of Common Stock for an aggregate purchase price of $417,099.96 through the exercise of a warrant (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the \"2014 Warrant\"). Following such exercise, no shares of Common Stock remain issuable upon exercise of the 2014 Warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 15, 2016, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 4,750,569 shares of Common Stock for an aggregate purchase price of $417,099.96 through the exercise of a warrant (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the \"2014 Warrant\"). Following such exercise, no shares of Common Stock remain issuable upon exercise of the 2014 Warrant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 15, 2016, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 4,750,569 shares of Common Stock for an aggregate purchase price of $417,099.96 through the exercise of a warrant (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the \"2014 Warrant\"). Following such exercise, no shares of Common Stock remain issuable upon exercise of the 2014 Warrant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On November 15, 2016, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 4,750,569 shares of Common Stock for an aggregate purchase price of $417,099.96 through the exercise of a warrant (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the \"2014 Warrant\"). Following such exercise, no shares of Common Stock remain issuable upon exercise of the 2014 Warrant."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On November 15, 2016, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 4,750,569 shares of Common Stock for an aggregate purchase price of $417,099.96 through the exercise of a warrant (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the \"2014 Warrant\"). Following such exercise, no shares of Common Stock remain issuable upon exercise of the 2014 Warrant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On November 15, 2016, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 4,750,569 shares of Common Stock for an aggregate purchase price of $417,099.96 through the exercise of a warrant (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the \"2014 Warrant\"). Following such exercise, no shares of Common Stock remain issuable upon exercise of the 2014 Warrant."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd (\"Mayne International\") and Mayne Pharma Group Limited (\"Mayne Group\"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":0.0878,"underlying":"Common Stock","underlying_shares":4750569},"source":{"system":"sec-edgar","filing":"0001144204-16-134828","document":"v453196_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000114420416134828/v453196_4.xml","form_type":"4"}},{"id":4555513,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":143703,"kind":"organization","name":"Mayne Pharma Ventures Pty Ltd","position":1,"cik":"0001611535","reported_name":"Mayne Pharma Ventures Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143704,"kind":"organization","name":"Mayne Pharma International Pty Ltd","position":2,"cik":"0001611534","reported_name":"Mayne Pharma International Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143705,"kind":"organization","name":"Mayne Pharma Group Ltd","position":3,"cik":"0001560183","reported_name":"Mayne Pharma Group Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-11-16T02:06:30.000Z","date":"2016-11-15","kind":"other","acquired":true,"shares":4860000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On November 15, 2016, Mayne Ventures acquired 4,860,000 shares of Common Stock for an aggregate purchase price of $583,200 through the partial exercise of a warrant (at a per share exercise price of $0.12) that was issued by the Issuer to Mayne Ventures on May 25, 2016 (the \"2016 Warrant\"). 23,504,236 shares of Common Stock remain issuable upon exercise of the 2016 Warrant. The 2016 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time on or prior to May 25, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On November 15, 2016, Mayne Ventures acquired 4,860,000 shares of Common Stock for an aggregate purchase price of $583,200 through the partial exercise of a warrant (at a per share exercise price of $0.12) that was issued by the Issuer to Mayne Ventures on May 25, 2016 (the \"2016 Warrant\"). 23,504,236 shares of Common Stock remain issuable upon exercise of the 2016 Warrant. The 2016 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time on or prior to May 25, 2021."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd (\"Mayne International\") and Mayne Pharma Group Limited (\"Mayne Group\"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer."}],"balance_after":197506132,"source":{"system":"sec-edgar","filing":"0001144204-16-134828","document":"v453196_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000114420416134828/v453196_4.xml","form_type":"4"}},{"id":4555512,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":143703,"kind":"organization","name":"Mayne Pharma Ventures Pty Ltd","position":1,"cik":"0001611535","reported_name":"Mayne Pharma Ventures Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143704,"kind":"organization","name":"Mayne Pharma International Pty Ltd","position":2,"cik":"0001611534","reported_name":"Mayne Pharma International Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143705,"kind":"organization","name":"Mayne Pharma Group Ltd","position":3,"cik":"0001560183","reported_name":"Mayne Pharma Group Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-11-16T02:06:30.000Z","date":"2016-11-15","kind":"other","acquired":true,"shares":333,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On November 15, 2016, Mayne Ventures acquired 333 shares of Common Stock for an aggregate purchase price of $24.98 through the exercise of a warrant (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015 (the \"2015 Warrant\"). No shares of Common Stock remain issuable upon exercise of the 2015 Warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On November 15, 2016, Mayne Ventures acquired 333 shares of Common Stock for an aggregate purchase price of $24.98 through the exercise of a warrant (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015 (the \"2015 Warrant\"). No shares of Common Stock remain issuable upon exercise of the 2015 Warrant."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd (\"Mayne International\") and Mayne Pharma Group Limited (\"Mayne Group\"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer."}],"balance_after":192646132,"source":{"system":"sec-edgar","filing":"0001144204-16-134828","document":"v453196_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000114420416134828/v453196_4.xml","form_type":"4"}},{"id":4555511,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":143703,"kind":"organization","name":"Mayne Pharma Ventures Pty Ltd","position":1,"cik":"0001611535","reported_name":"Mayne Pharma Ventures Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143704,"kind":"organization","name":"Mayne Pharma International Pty Ltd","position":2,"cik":"0001611534","reported_name":"Mayne Pharma International Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143705,"kind":"organization","name":"Mayne Pharma Group Ltd","position":3,"cik":"0001560183","reported_name":"Mayne Pharma Group Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-11-16T02:06:30.000Z","date":"2016-11-15","kind":"other","acquired":true,"shares":4750569,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On November 15, 2016, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 4,750,569 shares of Common Stock for an aggregate purchase price of $417,099.96 through the exercise of a warrant (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the \"2014 Warrant\"). Following such exercise, no shares of Common Stock remain issuable upon exercise of the 2014 Warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 15, 2016, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 4,750,569 shares of Common Stock for an aggregate purchase price of $417,099.96 through the exercise of a warrant (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the \"2014 Warrant\"). Following such exercise, no shares of Common Stock remain issuable upon exercise of the 2014 Warrant."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd (\"Mayne International\") and Mayne Pharma Group Limited (\"Mayne Group\"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer."}],"balance_after":192645799,"source":{"system":"sec-edgar","filing":"0001144204-16-134828","document":"v453196_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000114420416134828/v453196_4.xml","form_type":"4"}},{"id":4565717,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":143703,"kind":"organization","name":"Mayne Pharma Ventures Pty Ltd","position":1,"cik":"0001611535","reported_name":"Mayne Pharma Ventures Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143704,"kind":"organization","name":"Mayne Pharma International Pty Ltd","position":2,"cik":"0001611534","reported_name":"Mayne Pharma International Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143705,"kind":"organization","name":"Mayne Pharma Group Ltd","position":3,"cik":"0001560183","reported_name":"Mayne Pharma Group Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to Purchase Common Stock","published_at":"2016-11-08T02:17:18.000Z","date":"2016-11-04","kind":"other","acquired":false,"shares":33333000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"On November 4, 2016, Mayne Ventures acquired 33,333,000 shares of Common Stock for an aggregate purchase price of $2,499,975 through the partial exercise of a warrant to purchase 33,333,333 shares of Common Stock (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015. 333 shares of Common Stock remain issuable upon exercise of the 2015 Warrant. The 2015 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to May 15, 2020."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On November 4, 2016, Mayne Ventures acquired 33,333,000 shares of Common Stock for an aggregate purchase price of $2,499,975 through the partial exercise of a warrant to purchase 33,333,333 shares of Common Stock (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015. 333 shares of Common Stock remain issuable upon exercise of the 2015 Warrant. The 2015 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to May 15, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"On November 4, 2016, Mayne Ventures acquired 33,333,000 shares of Common Stock for an aggregate purchase price of $2,499,975 through the partial exercise of a warrant to purchase 33,333,333 shares of Common Stock (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015. 333 shares of Common Stock remain issuable upon exercise of the 2015 Warrant. The 2015 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to May 15, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On November 4, 2016, Mayne Ventures acquired 33,333,000 shares of Common Stock for an aggregate purchase price of $2,499,975 through the partial exercise of a warrant to purchase 33,333,333 shares of Common Stock (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015. 333 shares of Common Stock remain issuable upon exercise of the 2015 Warrant. The 2015 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to May 15, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On November 4, 2016, Mayne Ventures acquired 33,333,000 shares of Common Stock for an aggregate purchase price of $2,499,975 through the partial exercise of a warrant to purchase 33,333,333 shares of Common Stock (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015. 333 shares of Common Stock remain issuable upon exercise of the 2015 Warrant. The 2015 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to May 15, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On November 4, 2016, Mayne Ventures acquired 33,333,000 shares of Common Stock for an aggregate purchase price of $2,499,975 through the partial exercise of a warrant to purchase 33,333,333 shares of Common Stock (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015. 333 shares of Common Stock remain issuable upon exercise of the 2015 Warrant. The 2015 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to May 15, 2020."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On November 4, 2016, Mayne Ventures acquired 33,333,000 shares of Common Stock for an aggregate purchase price of $2,499,975 through the partial exercise of a warrant to purchase 33,333,333 shares of Common Stock (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015. 333 shares of Common Stock remain issuable upon exercise of the 2015 Warrant. The 2015 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to May 15, 2020."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On November 4, 2016, Mayne Ventures acquired 33,333,000 shares of Common Stock for an aggregate purchase price of $2,499,975 through the partial exercise of a warrant to purchase 33,333,333 shares of Common Stock (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015. 333 shares of Common Stock remain issuable upon exercise of the 2015 Warrant. The 2015 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to May 15, 2020."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd (\"Mayne International\") and Mayne Pharma Group Limited (\"Mayne Group\"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer."}],"balance_after":333,"derivative":{"exercise_price":0.075,"underlying":"Common Stock","underlying_shares":33333000},"source":{"system":"sec-edgar","filing":"0001144204-16-132226","document":"v452354_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000114420416132226/v452354_4.xml","form_type":"4"}},{"id":4565716,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":143703,"kind":"organization","name":"Mayne Pharma Ventures Pty Ltd","position":1,"cik":"0001611535","reported_name":"Mayne Pharma Ventures Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143704,"kind":"organization","name":"Mayne Pharma International Pty Ltd","position":2,"cik":"0001611534","reported_name":"Mayne Pharma International Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143705,"kind":"organization","name":"Mayne Pharma Group Ltd","position":3,"cik":"0001560183","reported_name":"Mayne Pharma Group Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to Purchase Common Stock","published_at":"2016-11-08T02:17:18.000Z","date":"2016-11-04","kind":"other","acquired":false,"shares":5500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On November 4, 2016, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 5,500,000 shares of Common Stock for an aggregate purchase price of $482,900 through the partial exercise of a warrant to purchase 10,250,569 shares of Common Stock (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the \"2014 Warrant\"). Following such partial exercise, 4,750,569 shares of Common Stock remain issuable upon exercise of the 2014 Warrant. The 2014 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to June 24, 2019."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On November 4, 2016, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 5,500,000 shares of Common Stock for an aggregate purchase price of $482,900 through the partial exercise of a warrant to purchase 10,250,569 shares of Common Stock (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the \"2014 Warrant\"). Following such partial exercise, 4,750,569 shares of Common Stock remain issuable upon exercise of the 2014 Warrant. The 2014 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to June 24, 2019."},{"field":"shares","element":"transactionShares","label":"F1","text":"On November 4, 2016, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 5,500,000 shares of Common Stock for an aggregate purchase price of $482,900 through the partial exercise of a warrant to purchase 10,250,569 shares of Common Stock (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the \"2014 Warrant\"). Following such partial exercise, 4,750,569 shares of Common Stock remain issuable upon exercise of the 2014 Warrant. The 2014 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to June 24, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 4, 2016, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 5,500,000 shares of Common Stock for an aggregate purchase price of $482,900 through the partial exercise of a warrant to purchase 10,250,569 shares of Common Stock (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the \"2014 Warrant\"). Following such partial exercise, 4,750,569 shares of Common Stock remain issuable upon exercise of the 2014 Warrant. The 2014 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to June 24, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 4, 2016, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 5,500,000 shares of Common Stock for an aggregate purchase price of $482,900 through the partial exercise of a warrant to purchase 10,250,569 shares of Common Stock (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the \"2014 Warrant\"). Following such partial exercise, 4,750,569 shares of Common Stock remain issuable upon exercise of the 2014 Warrant. The 2014 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to June 24, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On November 4, 2016, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 5,500,000 shares of Common Stock for an aggregate purchase price of $482,900 through the partial exercise of a warrant to purchase 10,250,569 shares of Common Stock (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the \"2014 Warrant\"). Following such partial exercise, 4,750,569 shares of Common Stock remain issuable upon exercise of the 2014 Warrant. The 2014 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to June 24, 2019."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On November 4, 2016, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 5,500,000 shares of Common Stock for an aggregate purchase price of $482,900 through the partial exercise of a warrant to purchase 10,250,569 shares of Common Stock (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the \"2014 Warrant\"). Following such partial exercise, 4,750,569 shares of Common Stock remain issuable upon exercise of the 2014 Warrant. The 2014 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to June 24, 2019."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On November 4, 2016, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 5,500,000 shares of Common Stock for an aggregate purchase price of $482,900 through the partial exercise of a warrant to purchase 10,250,569 shares of Common Stock (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the \"2014 Warrant\"). Following such partial exercise, 4,750,569 shares of Common Stock remain issuable upon exercise of the 2014 Warrant. The 2014 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to June 24, 2019."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd (\"Mayne International\") and Mayne Pharma Group Limited (\"Mayne Group\"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer."}],"balance_after":4750569,"derivative":{"exercise_price":0.0878,"underlying":"Common Stock","underlying_shares":5500000},"source":{"system":"sec-edgar","filing":"0001144204-16-132226","document":"v452354_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000114420416132226/v452354_4.xml","form_type":"4"}},{"id":4565715,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":143703,"kind":"organization","name":"Mayne Pharma Ventures Pty Ltd","position":1,"cik":"0001611535","reported_name":"Mayne Pharma Ventures Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143704,"kind":"organization","name":"Mayne Pharma International Pty Ltd","position":2,"cik":"0001611534","reported_name":"Mayne Pharma International Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143705,"kind":"organization","name":"Mayne Pharma Group Ltd","position":3,"cik":"0001560183","reported_name":"Mayne Pharma Group Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-11-08T02:17:18.000Z","date":"2016-11-04","kind":"other","acquired":true,"shares":33333000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On November 4, 2016, Mayne Ventures acquired 33,333,000 shares of Common Stock for an aggregate purchase price of $2,499,975 through the partial exercise of a warrant to purchase 33,333,333 shares of Common Stock (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015. 333 shares of Common Stock remain issuable upon exercise of the 2015 Warrant. The 2015 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to May 15, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On November 4, 2016, Mayne Ventures acquired 33,333,000 shares of Common Stock for an aggregate purchase price of $2,499,975 through the partial exercise of a warrant to purchase 33,333,333 shares of Common Stock (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015. 333 shares of Common Stock remain issuable upon exercise of the 2015 Warrant. The 2015 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to May 15, 2020."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd (\"Mayne International\") and Mayne Pharma Group Limited (\"Mayne Group\"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer."}],"balance_after":187895230,"source":{"system":"sec-edgar","filing":"0001144204-16-132226","document":"v452354_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000114420416132226/v452354_4.xml","form_type":"4"}},{"id":4565714,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":143703,"kind":"organization","name":"Mayne Pharma Ventures Pty Ltd","position":1,"cik":"0001611535","reported_name":"Mayne Pharma Ventures Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143704,"kind":"organization","name":"Mayne Pharma International Pty Ltd","position":2,"cik":"0001611534","reported_name":"Mayne Pharma International Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143705,"kind":"organization","name":"Mayne Pharma Group Ltd","position":3,"cik":"0001560183","reported_name":"Mayne Pharma Group Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-11-08T02:17:18.000Z","date":"2016-11-04","kind":"other","acquired":true,"shares":5500000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On November 4, 2016, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 5,500,000 shares of Common Stock for an aggregate purchase price of $482,900 through the partial exercise of a warrant to purchase 10,250,569 shares of Common Stock (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the \"2014 Warrant\"). Following such partial exercise, 4,750,569 shares of Common Stock remain issuable upon exercise of the 2014 Warrant. The 2014 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to June 24, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 4, 2016, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 5,500,000 shares of Common Stock for an aggregate purchase price of $482,900 through the partial exercise of a warrant to purchase 10,250,569 shares of Common Stock (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the \"2014 Warrant\"). Following such partial exercise, 4,750,569 shares of Common Stock remain issuable upon exercise of the 2014 Warrant. The 2014 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to June 24, 2019."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd (\"Mayne International\") and Mayne Pharma Group Limited (\"Mayne Group\"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer."}],"balance_after":154562230,"source":{"system":"sec-edgar","filing":"0001144204-16-132226","document":"v452354_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000114420416132226/v452354_4.xml","form_type":"4"}}]}